Johnson & Johnson Takes Over Manufacturing at Emergent Bio Plant in Baltimore
Johnson & Johnson Takes Over Manufacturing at Emergent Bio Plant in Baltimore
Attachment: Map
SUGAR LAND--April 6, 2021--Researched by Industrial Info Resources (Sugar Land, Texas)--After approximately 15 million doses of Johnson & Johnson's (J&J) COVID-19 vaccine had to be scrapped after a mix-up at Emergent Bio's CMO plant in Baltimore, Maryland, the pharma giant has completely taken over operation oversite at the beleaguered plant. J&J wants to emphasize the safety and viability of its "one-shot" COVID-19 vaccine.
The Emergent plant also is manufacturing AstraZeneca's COVID-19 vaccine, which has yet to be approved in the U.S. Already dealing with negative news reports regarding dangerous side effects of its product, the company has announced it will seek another company to take over the manufacturing from Emergent.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- U.S. Supplement Production Brings Millions in Spending
- Samsung Biologics Constructing ADC Plant in South Korea
- Data Center Activity Propels Virginia to $12.7 Billion of Projects Under Co...
- Pharma Company Zoetis Signs PPA with Scout Clean Energy to Support Growing ...
- China's Rongsheng Petrochemical Ups Role in Polyester Chips